Skip to content

10 mg

DRUG10 trials

Sponsors

Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy, Ultragenyx Pharmaceutical Inc., Uniwersytet Jagiellonski Collegium Medicum, Centrum Medyczne Ksztalcenia Podyplomowego, Reata Pharmaceuticals Inc., Reata Pharmaceuticals Inc.

Conditions

000 people may be affected by HCM3) and all-cause mortality (RR 2.5; 95% CI 1.8-3.4) with a mean follow-up of 7 years. HenceAF occurence is even higherAcute ischemic strokeCompulsive Sexual Behaviour DisorderCrohn's diseaseFriedreich's ataxiaGlycogen Storage Disease Type Ia (GSDIa)

Phase 1

Phase 2

Phase 3

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adenoassociated Virus Serotype 8-mediated Gene Transfer of Glucose-6-phosphatase in Patients With Glycogen Storage Disease Type Ia.
CompletedCTIS2023-508750-25-00
Ultragenyx Pharmaceutical Inc.Glycogen Storage Disease Type Ia (GSDIa)
Start: 2022-01-11End: 2025-12-22Target: 30Updated: 2026-01-19
The assessment of cysteinyl leukotriene receptor antagonist role in inhibition of atherosclerosis, proliferation and its influence on endothelial function in patients undergoing endovascular treatment due to peripheral arterial disease.
Active, not recruitingCTIS2024-511894-32-00
Uniwersytet Jagiellonski Collegium MedicumIschemia of the lower limbs in the course of obstructive artery disease
Start: 2021-08-19Target: 200Updated: 2024-07-01
Pharmacological treatment of compulsive sexual behaviour disorder
WithdrawnCTIS2024-514490-22-00
Centrum Medyczne Ksztalcenia PodyplomowegoCompulsive Sexual Behaviour Disorder
Target: 410Updated: 2024-09-30
Evaluation of the efficacy of topical treatment with budesonide in children with Crohn's disease located in the esophagus and/or stomach and/or duodenum - BETHESDa
RecruitingCTIS2024-519269-23-00
Medical University Of WarsawCrohn's disease
Start: 2024-03-27Target: 138Updated: 2025-07-10
A randomized, double-blind, placebo-controlled, multicenter study evaluating the effect of a 12-week DHEA combination of 20 mg and 2 mg prolonged-release melatonin on sleep quality and mood in postmenopausal women.
RecruitingCTIS2024-520234-30-00
The Pharmaceutical Company LEK-AM Sp. Zoo., Przedsiebiorstwo Farmaceutyczne Lek-Am Sp. z o.o.Menopause, sleep disorders in the postmenopausal period
Start: 2024-11-30Target: 100Updated: 2025-05-13

Phase 4